- Home
- CBIO vs AARD Comparison
CBIO vs AARD Comparison
Compare CBIO & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- AARD
- Stock Information
- Founded
- CBIO 2003
- AARD 2017
- Country
- CBIO United States
- AARD United States
- Employees
- CBIO N/A
- AARD N/A
- Industry
- CBIO
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- CBIO
- AARD Health Care
- Exchange
- CBIO Nasdaq
- AARD Nasdaq
- Market Cap
- CBIO 209.8M
- AARD 231.9M
- IPO Year
- CBIO N/A
- AARD 2025
- Fundamental
- Price
- CBIO $12.35
- AARD $10.39
- Analyst Decision
- CBIO Strong Buy
- AARD Strong Buy
- Analyst Count
- CBIO 5
- AARD 7
- Target Price
- CBIO $25.60
- AARD $31.43
- AVG Volume (30 Days)
- CBIO 111.3K
- AARD 176.4K
- Earning Date
- CBIO 11-23-2025
- AARD 11-13-2025
- Dividend Yield
- CBIO N/A
- AARD N/A
- EPS Growth
- CBIO N/A
- AARD N/A
- EPS
- CBIO N/A
- AARD N/A
- Revenue
- CBIO N/A
- AARD N/A
- Revenue This Year
- CBIO N/A
- AARD N/A
- Revenue Next Year
- CBIO N/A
- AARD N/A
- P/E Ratio
- CBIO N/A
- AARD N/A
- Revenue Growth
- CBIO N/A
- AARD N/A
- 52 Week Low
- CBIO $9.81
- AARD $4.88
- 52 Week High
- CBIO $21.40
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- CBIO 49.46
- AARD 37.01
- Support Level
- CBIO $12.30
- AARD $10.57
- Resistance Level
- CBIO $12.84
- AARD $12.16
- Average True Range (ATR)
- CBIO 0.72
- AARD 0.91
- MACD
- CBIO 0.07
- AARD -0.38
- Stochastic Oscillator
- CBIO 66.55
- AARD 9.61
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.